SCHEMBL4852735

SCHEMBL4852735

CCOP(=O)(OCC)[C@@H](CC(=O)c1cccc2ccccc12)NC(=O)OCC(Cl)(Cl)Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.58
▸ HPGD P15428 4/20 0.58
▸ THRB P10828 2/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ KDM4E B2RXH2 3/20 0.39
▸ GAA P10253 1/20 0.39
▸ CDC25B P30305 2/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ LMNA P02545 2/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ CDC25A P30304 1/20 0.36
▸ CDC25C P30307 1/20 0.36
▸ ADRB2 P07550 1/20 0.36
▸ ADRB1 P08588 1/20 0.36
▸ ADRB3 P13945 1/20 0.36
▸ PTPN1 P18031 1/20 0.36
▸ PLK1 P53350 1/20 0.36
▸ MAPT P10636 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4852733 1.00 ALDH1A1 (0.58) ALDH1A1HPGDTHRBL3MBTL1SMN1; SMN2
SCHEMBL4848464 0.83 SMN1; SMN2 (0.53) ALDH1A1HPGDTHRBL3MBTL1SMN1; SMN2
SCHEMBL5712075 0.83 SMN1; SMN2 (0.53) ALDH1A1HPGDTHRBL3MBTL1SMN1; SMN2
SCHEMBL4852741 0.83 ALDH1A1 (0.43) ALDH1A1HPGDTHRBL3MBTL1KDM4E
SCHEMBL4856385 0.82 MEN1 (0.44) ALDH1A1HPGDTHRBL3MBTL1SMN1; SMN2
SCHEMBL4856386 0.82 MEN1 (0.44) ALDH1A1HPGDTHRBL3MBTL1SMN1; SMN2
SCHEMBL4845951 0.79 MAPT (0.43) ALDH1A1HPGDTHRBL3MBTL1SMN1; SMN2
SCHEMBL4856844 0.79 MAPT (0.54) ALDH1A1HPGDTHRBL3MBTL1SMN1; SMN2
SCHEMBL4856854 0.79 MAPT (0.54) ALDH1A1HPGDTHRBL3MBTL1SMN1; SMN2
SCHEMBL4845948 0.79 MAPT (0.43) ALDH1A1HPGDTHRBL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1724275-B1 PROCESS FOR PRODUCING AMINOPHOSPHONIC ACID DERIVATIVE JAPAN SCIENCE & TECH AGENCY (JP) 2015-04-08 — — EP disclosed
US-7375244-B2 Production method for aminophosphonic acid derivatives JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2008-05-20 — — US disclosed
US-20070142658-A1 Production method for aminophosphonic acid derivatives JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2007-06-21 — — US disclosed
EP-1724275-A1 PROCESS FOR PRODUCING AMINOPHOSPHONIC ACID DERIVATIVE Japan Science and Technology Agency (JP) 2006-11-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142658-A1 Production method for aminophosphonic acid derivatives AASDHPPT, NPEPPS, DAO ALDH1A1 1956/4885HPGD 1536/4885THRB 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback